JNK1/2 and ERK1/2 provides vital clues about tumor recurrence and survival in hepatocellular carcinoma patients
JNK1/2 and ERK1/2 provides vital clues about tumor recurrence and survival in hepatocellular carcinoma patients
复制标题
JNK1/2和ERK1/2为肝细胞癌患者的肿瘤复发和生存提供了重要线索
DOI：
10.2217/fon-2018-0171
复制
发表时间：
2018-10-01
期刊：
影响因子：
3.3
通讯作者：
Yao, Hong
中科院分区：
文献类型：
--
作者：
Gao, Xiaoge;Shan, Wenhua;Yao, Hong
目的：探讨JNK 1/2和ERK 1/2在肝细胞癌（HCC）患者中的激活情况。患者和方法：在104例独特的HCC组织标本中测定和分析磷酸化JNK 1/2和-ERK 1/2（p-JNK 1/2和p-ERK 1/2）表达。结果：p-JNK 1/2和p-ERK 1/2的表达与临床病理特征无关。p-JNK 1/2高表达和p-ERK 1/2低表达预测HCC患者的肿瘤复发率显著降低。而p-JNK 1/2低表达和p-ERK 1/2高表达的HCC患者肿瘤复发率较高。p-JNK 1/2与肝癌患者的总生存期（OS）和无复发生存期（RFS）呈正相关，而p-ERK 1/2与总生存期（OS）和无复发生存期（RFS）呈负相关。此外，同时具有低p-JNK 1/2和高p-ERK 1/2的HCC患者具有较差的OS和RFS。而p-JNK 1/2高、p-ERK 1/2低的患者OS和RFS较好。结论：p-JNK 1/2和p-ERK 1/2分别或同时低表达和高表达的HCC患者，肿瘤复发率和OS均显著增高。
Aim: To explore JNK1/2 and ERK1/2 activation in hepatocellular carcinoma (HCC) patients. Patients & methods: Phosphorylated-JNK1/2 and -ERK1/2 (p-JNK1/2 and p-ERK1/2) expressions were determined and analyzed in 104 unique HCC tissue specimens. Results: Expression of p-JNK1/2 and p-ERK1/2 was not correlated with clinicopathological characteristics. High p-JNK1/2 and low p-ERK1/2 expressions predicated significantly lower tumor recurrence for HCC patients. However, HCC patients with low p-JNK1/2 and high p-ERK1/2 had higher tumor recurrence. Moreover, p-JNK1/2 positively, but p-ERK1/2 negatively, associated with overall survival (OS) and recurrence-free survival (RFS) in HCC patients. In addition, HCC patients with simultaneous low p-JNK1/2 and high p-ERK1/2 had poorer OS and RFS. On the contrary, patients with high p-JNK1/2 and low p-ERK1/2 presented better OS and RFS. Conclusion: HCC patients with low p-JNK1/2 and high p-ERK1/2 either independently or simultaneously, had significantly higher tumor recurrence and worse OS.